OVIDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Ovid Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$2.17+0.02 (+0.93%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
75.3%
147M of 195M shares
Institutional holders
131
47 new, 18 sold out
Net institutional buying
53M
In Q2 2026
Insider trades, 12 months
0 buys · 2 sales
Net sold $29.29K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 9,559,979 | 5.10% | 13G (passive) amendment | Jun 30, 2026 |
| Takeda Pharmaceutical Company Limited | 8,781,996 | 12.30% | 13G (passive) amendment | Dec 8, 2025 |
| Voting Shares Irrevocable Trust | 7,737,166 | 5.94% | 13G (passive) | Dec 31, 2025 |
| Janus Henderson Group PLC | 7,114,114 | 9.99% | 13G (passive) | Nov 28, 2025 |
| Dmitry Balyasny | 7,029,223 | 5.33% | 13G (passive) | Mar 31, 2026 |
| Rajeev Shah | 19,549,271 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
| Sirenia Capital Management LP | 18,031,333 | 9.90% | 13G (passive) | Mar 31, 2026 |
| Michael Cho | 15,635,484 | 9.10% | 13G (passive) amendment | Mar 31, 2026 |
| Affinity Asset Advisors, LLC | 15,143,728 | 7.90% | 13G (passive) amendment | Jun 30, 2026 |
| Peter Kolchinsky | 13,259,735 | 9.90% | 13G (passive) | Dec 11, 2025 |
| Robin C. John | 12,773,577 | 7.30% | 13G (passive) | Mar 31, 2026 |
| Affinity Healthcare Fund, LP | 12,149,166 | 9.00% | 13G (passive) | Dec 11, 2025 |
| Eventide Asset Management, LLC | 11,812,241 | 6.30% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 10,822,672 | 5.80% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of OVID | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 20,741,234 | 10.62% | $55.90M | New | 0.02% |
| Eventide Asset Management, LLC | 11,812,241 | 6.05% | $31.77M | +1,895,330 | 0.42% |
| BlackRock, Inc. | 10,823,480 | 5.54% | $29.12M | +9,290,197 | 0.00% |
| Ra Capital Management, L.P. | 10,500,968 | 5.38% | $28.25M | −213,032 | 0.25% |
| Affinity Asset Advisors, LLC | 10,144,562 | 5.19% | $27.29M | −491,756 | 1.23% |
| State Street Corp | 7,900,765 | 4.05% | $21.25M | +7,380,482 | 0.00% |
| Vanguard Capital Management LLC | 7,760,114 | 3.97% | $20.87M | +2,501,868 | 0.00% |
| ADAR1 Capital Management, LLC | 7,417,479 | 3.80% | $19.95M | +2,873,366 | 0.91% |
| Balyasny Asset Management L.P. | 6,719,076 | 3.44% | $18.07M | +1,186,003 | 0.02% |
| Adage Capital Partners Gp, L.L.C. | 6,163,781 | 3.16% | $16.58M | – | 0.02% |
| Federated Hermes, Inc. | 5,951,666 | 3.05% | $16.01M | +2,380,666 | 0.02% |
| Braidwell LP | 5,919,464 | 3.03% | $15.92M | New | 0.59% |
| Geode Capital Management, LLC | 4,072,653 | 2.09% | $10.96M | +2,754,562 | 0.00% |
| Silverarc Capital Management, LLC | 3,101,129 | 1.59% | $8.34M | +2,101,129 | 0.87% |
| Stempoint Capital LP | 2,417,283 | 1.24% | $6.50M | New | 1.12% |
| Ikarian Capital, LLC | 2,269,704 | 1.16% | $6.11M | −625,000 | 0.66% |
| Point72 Asset Management, L.P. | 1,945,727 | 1.00% | $5.23M | +625,117 | 0.01% |
| Sphera Funds Management Ltd. | 1,353,000 | 0.69% | $3.64M | −269,828 | 0.47% |
| Northern Trust Corp | 1,246,139 | 0.64% | $3.35M | +991,335 | 0.00% |
| Vanguard Fiduciary Trust Co | 1,140,753 | 0.58% | $3.07M | +447,497 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 131 | 147M | 75.3% | 47 / 33 | 27 / 18 | 71M | 19M |
| Q1 2026 | 103 | 105M | 53.8% | 30 / 33 | 20 / 10 | 53M | 7M |
| Q4 2025 | 84 | 62M | 31.6% | 20 / 25 | 24 / 13 | 42M | 8M |
| Q3 2025 | 81 | 36M | 18.5% | 25 / 18 | 23 / 14 | 11M | 10M |
| Q2 2025 | 71 | 36M | 18.4% | 17 / 16 | 22 / 27 | 4M | 15M |
| Q1 2025 | 82 | 46M | 23.8% | 10 / 20 | 28 / 9 | 5M | 6M |
| Q4 2024 | 82 | 48M | 24.4% | 14 / 24 | 21 / 7 | 3M | 4M |
| Q3 2024 | 75 | 48M | 24.5% | 10 / 31 | 15 / 8 | 9M | 4M |
| Q2 2024 | 74 | 47M | 24.3% | 14 / 22 | 25 / 21 | 5M | 9M |
| Q1 2024 | 81 | 52M | 26.6% | 12 / 29 | 22 / 8 | 2M | 4M |
| Q4 2023 | 77 | 53M | 27.4% | 17 / 25 | 17 / 3 | 12M | 0M |
| Q3 2023 | 64 | 42M | 21.7% | 5 / 18 | 20 / 9 | 2M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of OVID | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 5,653,216 | 2.89% | $15.21M | 0.00% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 4,920,517 | 2.52% | $13.24M | 0.12% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 3,885,284 | 1.99% | $10.45M | 0.01% | Jun 30, 2026 |
| Federated Hermes Kaufmann Small Cap Fund | 2,380,666 | 1.22% | $5.29M | 0.19% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 1,952,622 | 1.00% | $5.25M | 0.01% | Jun 30, 2026 |
| Eventide Healthcare & Life Sciences Fund | 1,934,257 | 0.99% | $5.20M | 0.29% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,676,723 | 0.86% | $3.72M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 1,214,167 | 0.62% | $3.27M | 0.02% | Jun 30, 2026 |
| Nuveen Equity Index Fund | 646,552 | 0.33% | $1.44M | 0.00% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 613,458 | 0.31% | $1.67M | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 514,160 | 0.26% | $1.38M | 0.09% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 372,024 | 0.19% | $825.89K | 0.01% | Jul 31, 2026 |
| Master Small Cap Index Series | 286,234 | 0.15% | $769.97K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 215,714 | 0.11% | $588.90K | 0.00% | May 31, 2026 |
| Nuveen Small Cap Blend Index Fund | 203,812 | 0.10% | $452.46K | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jeremy M. Levin | Executive Chairman, Director | 3,770,509 | 1.93% | Mar 25, 2026 |
| Margaret A. Alexander | President and CEO, Director | 61,750 | 0.03% | Mar 2, 2026 |
| Charles Ross Carter | Chief Financial Officer | 44,375 | 0.02% | Jul 8, 2026 |
| Jeffrey A. Rona | CBFO | 156,313 | 0.08% | Mar 2, 2026 |
| Anna Greka | Director | – | – | Jun 17, 2026 |
| Bart Friedman | Director | 8,789 | 0.00% | Apr 9, 2026 |
| Stelios Papadopoulos | Director | 217,578 | 0.11% | Apr 9, 2026 |
| Kevin Joseph Fitzgerald | Director | 17,578 | 0.01% | Apr 9, 2026 |
| Karen Bernstein | Director | 20,000 | 0.01% | Mar 2, 2026 |
| Barbara Gayle Duncan | Director | – | – | Mar 2, 2026 |
| Pharmaceutical Co Ltd Takeda | 10% owner | 7,531,996 | 3.86% | Dec 9, 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10% owner | 8,781,996 | 4.50% | Dec 9, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Charles Ross Carter Chief Financial Officer | Jul 6, 2026 | Award | +50,000 | – | – | 94,375 |
| Kevin Joseph Fitzgerald Director | Apr 7, 2026 | Award | +17,578 | $2.56 | $45.00K | 17,578 |
| Stelios Papadopoulos Director | Apr 7, 2026 | Award | +17,578 | $2.56 | $45.00K | 217,578 |
| Bart Friedman Director | Apr 7, 2026 | Award | +8,789 | $2.56 | $22.50K | 8,789 |
| Jeremy M. Levin Executive Chairman, Director | Mar 23, 2026 | Option exercise | +47,333 | $1.40 | $66.27K | 3,735,048 |
| Jeffrey A. Rona CBFO | Feb 26, 2026 | Award | +68,125 | – | – | 156,313 |
| Margaret A. Alexander President and CEO, Director | Feb 23, 2026 | Sale | −11,656 | $1.45 | $16.90K | 61,750 |
| Jeffrey A. Rona CBFO | Feb 23, 2026 | Sale | −8,541 | $1.45 | $12.38K | 88,188 |
| Jeremy M. Levin CEO, Director | Dec 15, 2025 | Conversion | +71,000 | – | – | 3,687,715 |
| Takeda Pharmaceuticals U.S.A., Inc. 10% owner | Dec 8, 2025 | Conversion | +1,250,000 | – | – | 7,000,000 |
| Jeffrey A. Rona CBFO | Feb 26, 2025 | Sale | −3,902 | $0.56 | $2.19K | 67,973 |
| Margaret A. Alexander President and COO | Feb 26, 2025 | Sale | −5,279 | $0.56 | $2.96K | 73,406 |
| Jeffrey A. Rona CBFO | Feb 20, 2025 | Award | +43,750 | – | – | 71,875 |
| Margaret A. Alexander President and COO | Feb 20, 2025 | Award | +43,750 | – | – | 78,685 |
| Margaret A. Alexander President and COO | Jan 27, 2025 | Buy | +6,810 | $0.73 | $4.97K | 34,935 |
| Jeremy M. Levin CEO, Director | Mar 18, 2024 | Buy | +18,248 | $2.76 | $50.36K | 3,616,715 |
| Jason Tardio Chief Operating Officer | Feb 22, 2024 | Award | +28,125 | – | – | 28,125 |
| Jeffrey A. Rona CBFO | Feb 22, 2024 | Award | +28,125 | – | – | 28,125 |
| Thomas Michael Perone General Counsel, Secretary | Feb 22, 2024 | Award | +28,125 | – | – | 28,125 |
| Jeremy M. Levin CEO, Director | Dec 4, 2023 | Gift | −573,275 | – | – | 4,171,742 |
| Jeremy M. Levin CEO, Director | Dec 4, 2023 | Gift | −573,275 | – | – | 3,598,467 |
| Jason Tardio Chief Operating Officer | Sep 12, 2022 | Sale | −17,344 | $2.15 | $37.29K | 0 |
| Pharmaceutical Co Ltd Takeda 10% owner | Jul 1, 2022 | Other | +5,750,000 | – | – | 5,750,000 |
| Pharmaceutical Co Ltd Takeda 10% owner | Jul 1, 2022 | Other | −5,750,000 | – | – | 0 |
| Amit Rakhit President and CMO | Jul 14, 2021 | Sale | −34,017 | $3.71 | $126.20K | 726,823 |
| Amit Rakhit President and CMO | Jul 14, 2021 | Option exercise | +34,017 | $1.89 | $64.29K | 760,840 |
| Jeremy M. Levin CEO, Director, 10% owner | Aug 28, 2020 | Buy | +8,488 | $5.84 | $49.57K | 5,792,530 |
| Pharmaceutical Co Ltd Takeda 10% owner | Oct 8, 2019 | Buy | +2,000,000 | $2.50 | $5.00M | 5,750,000 |
| Jeremy M. Levin CEO, Director, 10% owner | Oct 8, 2019 | Buy | +60,000 | $2.50 | $150.00K | 4,736,529 |
| Jeremy M. Levin CEO, Director | Sep 20, 2019 | Gift | −465,116 | – | – | 0 |
| Karen Bernstein Director | Feb 26, 2019 | Buy | +10,000 | $2.02 | $20.20K | 20,000 |
| Jeremy M. Levin CEO, Director, 10% owner | Feb 22, 2019 | Buy | +75,000 | $2.00 | $150.00K | 4,676,529 |
| Karen Bernstein Director | Aug 14, 2018 | Buy | +10,000 | $6.23 | $62.30K | 10,000 |
| Douglas E. Williams Director | Aug 14, 2018 | Buy | +5,000 | $6.49 | $32.45K | 5,000 |
| Jeremy M. Levin CEO, Director, 10% owner | Aug 25, 2017 | Buy | +15,334 | $7.15 | $109.64K | 4,601,529 |
| Jeremy M. Levin CEO, Director, 10% owner | May 10, 2017 | Conversion | +35,461 | – | – | 35,461 |
| Jeremy M. Levin CEO, Director, 10% owner | May 10, 2017 | Conversion | +400,150 | – | – | 4,586,195 |
| Matthew During President and CSO, Director, 10% owner | May 10, 2017 | Conversion | +28,245 | – | – | 4,307,314 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| A. Rona Jeffrey Affiliated Stockholder | Aug 24, 2026 | 325,000 | $910.00K | Aug 24, 2026 | Stock Option Exercise |
| A. Rona Jeffrey Affiliated Stockholder | Aug 14, 2026 | 150,000 | $420.00K | Aug 14, 2026 | ESPP Purchase |